期刊文献+

加替沙星不良反应特点与防范 被引量:1

Understand and prevent the ADR of Gatifloxaxin
下载PDF
导出
摘要 国外已对加替沙星影响心脏功能和血糖代谢的不良反应予以警戒。近期,我院发现加替沙星注射剂引起心悸、静脉炎等不良反应,并出现了房室传导阻滞和过敏性休克等多例较为严重的不良反应病例。提示国内也应注意加替沙星临床使用的安全性,不宜将其作为常用抗菌药品在门诊患者中大量使用。 Medical teams in some countries have been warned that Gatifloxaxin can influence on cardiac function and dysglycemia. The incidence rate of adverse reaction induced by Gatifloxaxin injection is quite high in the clinic of Fengtai Hospital recently. The most common ADR are palpitation and phlebitis. The serious ADR are atrioventricular block and allergic shock.The clinical safety of gat; floxaxin should be taken care of and gatifloxaxin should not be suitable to use as common antibacterial agent in outpatients.
作者 雷波 张树荣
机构地区 北京丰台医院
出处 《中国药物警戒》 2006年第6期362-364,共3页 Chinese Journal of Pharmacovigilance
关键词 加替沙星 Q—T间期延长 血糖代谢紊乱 药物警戒 gatifloxaxin prolonged Q-T dysglycemia pharmacovigilance
  • 相关文献

参考文献9

  • 1[1]Summary of safety-related drug labeling changes changes approved by FDA center for drug evaluation and research(CDER).[EB/OL].2001-10-10[2006-8-25].http://www.fda.gov/med watch/safety/2001/aug01.html. 被引量:1
  • 2[2]Summary of safety-related drug labeling changes changes approved by FDA center for drug evaluation and research(CDER).[EB/OL].2001-11-29[2006-8-25].http://www.fda.gov/med watch/safety/2001/oct01.html. 被引量:1
  • 3国家药品不良反应监测中心,国家药品监督管理局药品评价中心.日本针对加替沙星的致医生函[J].中国药品不良反应通讯,2003,4(总第35期):27. 被引量:3
  • 4[4]Saraya A,Yokokura M,Gonoi T,et al.Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+channels[J].Eur J Pharmacol.2004,497:111-117. 被引量:1
  • 5[5]Joseph S,Bertino Jr,Robert C,et al.Gatifloxacin-associated corrected QT interval prolongation,torsades de points and ventricular fibrillation in patients with hnown risk factors[J].CID.2002,34(15):861-863. 被引量:1
  • 6李燕,李晓波.酷似脑血管意外的低血糖昏迷8例分析[J].首都医药,2002,9(3):71-71. 被引量:2
  • 7[7]何礼贤.左氧氟沙星(可乐必妥)治疗LRTI临床应用的拓展和安全性再评价[N].中国医学论坛报,2005-10-20(27版). 被引量:4
  • 8[8]Frothingham R.Quinoione safety and efficacy more important than potency.[EB/OL].2004-4-5[2006-1-3].http://www.cdc.gov/ncidod/eid/vol 11no1/03-0307.html. 被引量:1
  • 9[9]Frothingham R.Quinoione safety and efficacy(responses).[EB/OL].2005-5-19[2005-12-30].http://www.cdc.gov/ncidod/eid/vol 11no06/04-0740-05-0581.html. 被引量:1

共引文献5

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部